This question is posed to those who review (and negotiate) Confidentiality
Agreements for investigators who want to participate in industry-sponsored
clinical trials.  We are experiencing increasing resistance from Sponsors
and/or their CRO's to include language in the Agreement that states they
will mark their materials as confidential, and if information is conveyed
verbally, they will reduce that information to writing and mark it as
confidential.  Are you having similar experiences, and if so, how are you
handling it?

All comments and suggestions will be appreciated.

Thanks in advance.

Valerie

Valerie A. Blake
Assistant Director
North Shore-Long Island Jewish Health System
Office of Grants and Contracts
5 Dakota Drive, Suite 307
Lake Success, NY  11042
Phone:  (516) 719-3100
Fax:  (516) 719-3110
xxxxxx@nshs.edu

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================